369 related articles for article (PubMed ID: 26821505)
41. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic approach to familial Mediterranean fever: a review update.
Ozturk MA; Kanbay M; Kasapoglu B; Onat AM; Guz G; Furst DE; Ben-Chetrit E
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S77-86. PubMed ID: 21968242
[TBL] [Abstract][Full Text] [Related]
43. Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases.
Haj-Yahia S; Ben-Zvi I; Lidar M; Livneh A
Joint Bone Spine; 2021 Oct; 88(5):105201. PubMed ID: 33932573
[TBL] [Abstract][Full Text] [Related]
44. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.
Cetin P; Sari I; Sozeri B; Cam O; Birlik M; Akkoc N; Onen F; Akar S
Inflammation; 2015 Feb; 38(1):27-31. PubMed ID: 25139580
[TBL] [Abstract][Full Text] [Related]
46. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
Erden A; Batu ED; Sarı A; Sönmez HE; Armagan B; Demir S; Fırat E; Bilginer Y; Bilgen SA; Karadağ Ö; Kalyoncu U; Kiraz S; Ertenli I; Özen S; Akdogan A
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):97-102. PubMed ID: 30418112
[TBL] [Abstract][Full Text] [Related]
47. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
[TBL] [Abstract][Full Text] [Related]
48. Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors.
Levinsky Y; Azani L; Shkalim Zemer V; Chodick G; Tal R; Harel L; Amarilyo G
Semin Arthritis Rheum; 2023 Aug; 61():152211. PubMed ID: 37201215
[TBL] [Abstract][Full Text] [Related]
49. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis.
Ozdogan H; Ugurlu S; Uygunoglu U; Tutuncu M; Gul A; Akman G; Siva A
Mult Scler Relat Disord; 2020 Oct; 45():102332. PubMed ID: 32645635
[TBL] [Abstract][Full Text] [Related]
50. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
[TBL] [Abstract][Full Text] [Related]
51. Colchicine modulates expression of pro-inflammatory genes in neutrophils from patients with familial Mediterranean fever and healthy subjects.
Manukyan G; Petrek M; Tomankova T; Martirosyan A; Tatyan M; Navratilova Z; Paulu D; Kriegova E
J Biol Regul Homeost Agents; 2013; 27(2):329-36. PubMed ID: 23830384
[TBL] [Abstract][Full Text] [Related]
52. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment.
Alpa M; Roccatello D
Drug Des Devel Ther; 2015; 9():1983-7. PubMed ID: 25945034
[TBL] [Abstract][Full Text] [Related]
53. [Familial Mediterranean Fever (FMF): from diagnosis to treatment].
Medlej-Hashim M; Loiselet J; Lefranc G; Mégarbané A
Sante; 2004; 14(4):261-6. PubMed ID: 15745878
[TBL] [Abstract][Full Text] [Related]
54. Canakinumab for the treatment of familial Mediterranean fever.
Ozdogan H; Ugurlu S
Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
[TBL] [Abstract][Full Text] [Related]
55. Evidence-based recommendations for the practical management of Familial Mediterranean Fever.
Hentgen V; Grateau G; Kone-Paut I; Livneh A; Padeh S; Rozenbaum M; Amselem S; Gershoni-Baruch R; Touitou I; Ben-Chetrit E
Semin Arthritis Rheum; 2013 Dec; 43(3):387-91. PubMed ID: 23742958
[TBL] [Abstract][Full Text] [Related]
56. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
Yildirim T; Yilmaz R; Uzerk Kibar M; Erdem Y
J Nephrol; 2018 Jun; 31(3):453-455. PubMed ID: 29446001
[TBL] [Abstract][Full Text] [Related]
57. An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial.
Koga T; Hagimori N; Sato S; Morimoto S; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Jan; 99(1):e18328. PubMed ID: 31895769
[TBL] [Abstract][Full Text] [Related]
58. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF?
Terekeci HM; Oktenli C; Ozgurtas T; Nalbant S; Top C; Celik S; Tapan S; Kucukardali Y; Sanisoglu YS; Solmazgul E; Sahan B; Sayan O
J Rheumatol; 2008 Oct; 35(10):2024-9. PubMed ID: 18785307
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine.
Grossman C; Farberov I; Feld O; Livneh A; Ben-Zvi I
Rheumatol Int; 2019 Mar; 39(3):517-523. PubMed ID: 30604205
[TBL] [Abstract][Full Text] [Related]
60. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.
Kiraz S; Ertenli I; Arici M; Calgüneri M; Haznedaroglu I; Celik I; Pay S; Kirazli S
Clin Exp Rheumatol; 1998; 16(6):721-4. PubMed ID: 9844766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
